Evidence map›Paper›PMID 21326323›Full record

ReviewNature reviews. Cancer2011

Novel roles for Slits and netrins: axon guidance cues as anticancer targets?

Patrick Mehlen, Céline Delloye-Bourgeois, Alain Chédotal

Open access · hybridAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 163 papers.

0numbers the graph read from it
0cells of the map it votes in
163citing papers in PubMed
6.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

163 citing papers in PubMed, 260 citations in OpenAlex.

  1. Novel netrin-1-Unc5b-Klf4 axis balances AT2 survival in experimental bronchopulmonary dysplasia.American journal of respiratory cell and molecular biology · 2026
    Article
  2. The CaThe Journal of biological chemistry · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Immunomodulation by allograft endothelial cells.Frontiers in transplantation · 2025
    Review
  17. Review
  18. Implications of draxin in neurological disorders.Frontiers in cell and developmental biology · 2025
    Review
  19. Article
  20. Article

103 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Patrick MehlenApoptosis, Cancer and Development Laboratory-Equipe labellisée La Ligue-, CRCL UMR INSERM U1052 CNRS 5286, Université de Lyon, Centre Léon Bérard, 69008 Lyon, France. mehlen@lyon.fnclcc.fr
Céline Delloye-Bourgeois
Alain Chédotal
Inserm · FRSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past few years, several genes, proteins and signalling pathways that are required for embryogenesis have been shown to regulate tumour development and progression by playing a major part in overriding antitumour safeguard mechanisms. These include axon guidance cues, such as Netrins and Slits. Netrin 1 and members of the Slit family are secreted extracellular matrix proteins that bind to deleted in colorectal cancer (DCC) and UNC5 receptors, and roundabout receptors (Robos), respectively. Their expression is deregulated in a large proportion of human cancers, suggesting that they could be tumour suppressor genes or oncogenes. Moreover, recent data suggest that these ligand-receptor pairs could be promising targets for personalized anticancer therapies.

Indexed as

AnimalsAxonsHumansNeoplasmsNerve Growth FactorsNerve Tissue ProteinsNetrin-1Protein BindingTumor Suppressor ProteinsNerve Growth FactorsNerve Tissue ProteinsNetrin-1NTN1 protein, humanTumor Suppressor Proteins

Identifiers

PMID21326323
OpenAlexW2048888260

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.